42d0c1c2bd
- Source: inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md - Domain: health - Claims: 2, Entities: 2 - Enrichments: 0 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
2.8 KiB
Lykos Therapeutics
Type: Pharmaceutical company (formerly MAPS Public Benefit Corporation) Focus: MDMA-assisted therapy for PTSD Status: Post-CRL restructuring (75% staff reduction as of August 2024)
Overview
Lykos Therapeutics (formerly the public benefit corporation arm of MAPS - Multidisciplinary Association for Psychedelic Studies) developed MDMA-assisted therapy for post-traumatic stress disorder. The company conducted pivotal Phase 3 trials (MAPP1 and MAPP2) that showed statistically significant reductions in PTSD symptoms measured by CAPS-5 scores.
Regulatory History
FDA Complete Response Letter (August 9, 2024)
The FDA rejected Lykos's New Drug Application for MDMA-assisted therapy, citing:
-
Functional unblinding: MDMA's pronounced psychoactive effects (empathogenic, euphoric) meant participants could reliably identify whether they received active drug or placebo, biasing self-reported outcomes. The FDA Psychopharmacologic Drugs Advisory Committee voted 10-1 that functional unblinding compromised trial validity.
-
Data reliability concerns: Systematic documentation issues for abuse-related adverse events and site oversight problems at clinical trial sites.
-
Cardiovascular risk: Acute cardiovascular effects (heart rate and blood pressure elevation) raised safety concerns for broader population use.
-
Insufficient duration data: Inadequate data to guide clinicians on duration of MDMA's therapeutic effects.
The FDA required an additional Phase 3 study. No resubmission timeline has been announced as of May 2026.
FDA Advisory Committee Review (June 4, 2024)
- Benefit-risk vote: 8-1 adverse
- Functional unblinding vote: 10-1 adverse (essentially unanimous that blinding failure invalidated trial methodology)
Organizational Impact
- Laid off approximately 75% of staff following the Complete Response Letter
- Separated operations from MAPS PBC (nonprofit parent organization)
- Meeting with FDA to request reconsideration and discuss resubmission pathway
Clinical Trial Program
Phase 3 Trials:
- MAPP1 and MAPP2 showed statistically significant PTSD symptom reductions
- Used inert placebo comparator (later identified as methodological flaw)
- Efficacy demonstrated but methodology deemed invalid by FDA
Timeline
- 2024-06-04 — FDA Psychopharmacologic Drugs Advisory Committee votes 10-1 against approval based on functional unblinding concerns
- 2024-08-09 — FDA issues Complete Response Letter rejecting NDA, requiring additional Phase 3 study
- 2024-08 — Lykos lays off ~75% of staff following CRL
- 2025-09-04 — Complete Response Letter made public
Sources
- FDA Complete Response Letter, August 9, 2024
- Psychiatric Times coverage, September 2025
- STAT News reporting, October 2025